| pioglitazone / Generic mfg. |
ChiCTR-RNC-12001949: Genetic polymorphisms affect therapeutic efficacy of Pioglitazone in Chinese Patients with type 2 diabetes |
|
|
| Completed | N/A | 100 | | none | The Third Xiangya Hospital, Central South University; The Third Xiangya Hospital, Central South University, self-funded | diabetes | | | | |
ChiCTR-IOR-15006343: The application of new insulin resistance index evaluation of two kinds of drugs for the treatment of PCOS |
|
|
| Not yet recruiting | N/A | 72 | | 500mgTid metformin for 12 weeks, 2 weeks elution and 15mgQd pioglitazone for 12 weeks. ;15mg Qd pioglitazone for 12 weeks, 2 weeks elution and 500mgTid metformin for 12 weeks | Beijing Tsinghua changgeng Hospital; Beijing Tsinghua changgeng Hospital, Merck Serono Diabetes Research Foundation | insulin resistance | | | | |
ChiCTR1800015504: Pioglitazone adjuntive therapy for bipolar depression: the efficacy and potential mechanisms |
|
|
| Recruiting | N/A | 90 | | pioglitazone adjuntive therapy ;blank control | Peking University Sixth Hospital; Peking University Sixth Hospital, the National Natural Science Foundation of China | Bipolar Disorder | | | | |
NCT05422092: Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease |
|
|
| Not yet recruiting | N/A | 80 | NA | Canagliflozin, Canagliflozin tablets, Pioglitazone, Pioglitazone Hydrochloride Tablets | First Affiliated Hospital Xi'an Jiaotong University | Type 2 Diabetes Mellitus With Complication | 01/23 | 12/23 | | |
| Active, not recruiting | N/A | 150 | RoW | Metformin, Glucophage, Gliclazide, Diamicron, Diamicron MR, Sitagliptin, Januvia, Liraglutide, Victoza, Pioglitazone, Actos, Dapagliflozin, Forxiga, Farxiga, human insulin, novorapid, glargine | Weill Cornell Medical College in Qatar, Hamad Medical Corporation, Sidra Medical and Research Center, University of Hull | Diabetes Mellitus Type 2 | 10/23 | 10/24 | | |
| Recruiting | N/A | 60 | US | Pioglitazone, Thiazolidinedione, Placebo | University of Texas Southwestern Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Takeda Pharmaceuticals North America, Inc. | Uric Acid Kidney Stone Disease | 11/24 | 12/24 | | |
| Completed | N/A | 201 | US | Brief Behavioral Compliance Enhancement Treatment, BBCET | VA Office of Research and Development | Alcohol Use Disorder | 03/24 | 05/24 | | |
| Recruiting | N/A | 60 | Europe | Pioglitazone 45 mg, Empagliflozin 25 MG, Semaglutide 7 MG | Karolinska Institutet, Karolinska University Hospital | Type 2 Diabetes | 09/24 | 12/32 | | |
NCT06107153: Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control |
|
|
| Recruiting | N/A | 200 | RoW | Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Lantus, Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Kombiglyze, Pioglitazone 30mg, Actos | University of Basrah | Type2diabetes | 04/25 | 05/25 | | |
